Evidence map›Paper›PMID 42595969›Full record

ReviewPhytotherapy research : PTR2026

Immunomodulatory Properties of Withania somnifera: Regulation of Innate Immune Cells and Clinical Implications.

Rana Yukta, Sonalika Gupta, Gagandeep Kaur, Partha Sarathi Mondal, Milirani Das, Anagha Ranade, Alok Kumar Srivastava, Sachin Kumar, Manoj Kumar Barthwal, Madhu Dikshit

Abstract readReview
In one paragraph

Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rana YuktaPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Sonalika GuptaPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Gagandeep KaurPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Partha Sarathi MondalPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Milirani DasPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Anagha RanadeCentral Council for Research in Ayurvedic Sciences, Ministry of Ayush, New Delhi, India.
Alok Kumar SrivastavaRegional Ayurveda Research Institute, Lucknow, India.
Sachin KumarPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.ORCID https://orcid.org/0000-0002-3835-8935
Manoj Kumar BarthwalPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.
Madhu DikshitPharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India.ORCID https://orcid.org/0000-0002-2777-0940

Funding

CCRAS HQ-Proj011/20/2022-ProjMinistry of Ayush, Government of India CoES-12011/5/2022-SCHEMEScience and Engineering Research Board NSC/2025/000020
6 · The paper itself

Abstract

Withania somnifera (L.) Dunal (WS), commonly known as Ashwagandha, is a prominent medicinal herb in Ayurveda, with extensive therapeutic potential attributed to its diverse phytochemical profile. This review critically examines the immunomodulatory properties of WS, focusing on innate immune cell populations, including neutrophils, eosinophils, macrophages, dendritic cells, and natural killer (NK) cells. Bioactive constituents, particularly withanolides and withaferin A derived mainly from roots and leaves, orchestrate immune responses through modulation of cytokine networks, enhancement of phagocytic activity, and attenuation of oxidative stress. WS constituents regulate key signaling pathways, including ERK, NF-κB, and JAK/STAT, at transcriptional and translational levels. WS exhibits a dual immunoregulatory role by enhancing innate immune cell functionality while suppressing pathological inflammation in allergic and chronic inflammatory disorders. However, critical gaps persist in elucidating its molecular mechanisms, establishing phytochemical standardization, and defining context-specific dosing regimens. Collectively, current evidence positions WS as a promising candidate for the management of autoimmune, infectious, and inflammatory diseases. However, it further highlights the need for rigorous mechanistic studies and well-designed clinical trials to enable its integration into evidence-based therapeutics.

Indexed as

Immunity, InnateImmunologic FactorsImmunomodulating AgentsPlant ExtractsWithaniaAnimalsCytokinesDendritic CellsEosinophilsHumansKiller Cells, NaturalMacrophagesNeutrophilsSignal TransductionWithanolidesAshwagandhaCytokinesImmunologic FactorsImmunomodulating AgentsPlant Extractswithaferin AWithanolidesimmune cellsimmunomodulationmacrophage and neutrophilsphytomedicineWithania somnifera

Identifiers

PMID42595969
PMCPMC13636102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.